A. Finnerty

Marrow changes and reduced proliferative capacity of mesenchymal stromal cells from patients with "no-option" critical limb ischemia; observations on feasibility of the autologous approach from a clinical trial.

S. Walsh, L. Howard, A. Hayat, 2022, Cytotherapy.

Autologous bone marrow mesenchymal stromal cell therapy for "no-option" critical limb ischemia is limited by karyotype abnormalities.

S. Walsh, L. Howard, E. Kavanagh, 2020, Cytotherapy.

GMP-Compliant Production of Autologous Adipose-Derived Stromal Cells in the NANT 001 Closed Automated Bioreactor

Deirdre M. Jones, G. Shaw, M. Murphy, 2022, Frontiers in Bioengineering and Biotechnology.

Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM)

N. Perico, G. Remuzzi, P. Ruggenenti, 2023, Journal of the American Society of Nephrology : JASN.